Work

Abstract CT060: ACTION: A randomized phase 3 study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct060

Authors: Isabel Arrillaga-Romany, Andrew Lassman, Susan L. McGovern, Sabine Mueller, Louis B. Nabors, Martin van den Bent, Michael Vogelbaum, Joshua E. Allen, Allen S. Melemed, Rohinton S. Tarapore, Dewen Yang, Patrick Wen, Timothy Cloughsey

Institutions: Massachusetts General Hospital, NewYork–Presbyterian Hospital, Herbert Irving Comprehensive Cancer Center, Columbia University, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, University of Alabama at Birmingham, Erasmus MC, Erasmus MC Cancer Institute, Moffitt Cancer Center, Chimerix (United States), Center for Neuro-Oncology, Dana-Farber Cancer Institute, University of California, Los Angeles

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365517017

Cites:

Cited by:

Related to: 10